MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Donati, Benedetta ^a   Dongiovanni, Paola ^b   Romeo, Stefano ^c,d   Meroni, Marica ^a   McCain, Misti ^e,f   Miele, Luca ^g   Petta, Salvatore ^h   Maier, Silvia ⁱ   Rosso, Chiara ^j   De Luca, Laura ⁱ   Vanni, Ester ^j   Grimaudo, Stefania ^h   Romagnoli, Renato ^k   Colli, Fabio ^k   Ferri, Flaminia ^l   Mancina, Rosellina Margherita ^c   Iruzubieta, Paula ^m   Craxi, Antonio ^h   Fracanzani, Anna Ludovica ^a,b   Grieco, Antonio ^g   Corradini, Stefano Ginanni ^l   Aghemo, Alessio ^b   Colombo, Massimo ^a,n   Soardo, Giorgio ⁱ   Bugianesi, Elisabetta ^j   Reeves, Helen ^e,f   Anstee, Quentin M ^f,m   Fargion, Silvia ^a,b   Valenti, Luca ^a,b   more..

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^h UNIVERSITY OF PALERMO   (Italy)

ⁱ UNIVERSITY OF UDINE   (Italy)

^j UNIVERSITY OF TURIN   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m NEWCASTLE UNIVERSITY   (United Kingdom)

ⁿ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; MBOAT7 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADULT; AGED; ALLELE; COMPLICATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; GENOTYPE; HUMAN; ITALY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATHOLOGY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ACYLTRANSFERASES; ADULT; AGED; ALLELES; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 85021740720     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-04991-0     Document Type: Article

References (46)

1. Dongiovanni, P., Romeo, S. & Valenti, L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 20, 12945-12955 (2014).
2. Dyson, J. et al. Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 60, 110-117 (2014).
3. Baffy, G., Brunt, E. M. & Caldwell, S. H. Hepatocellular carcinoma in non-Alcoholic fatty liver disease: An emerging menace. J Hepatol 56, 1384-1391 (2012).
4. Bugianesi, E. et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123, 134-140 (2002).
5. Younossi, Z. & Henry, L. Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. Gastroenterology 150, 1778-1785 (2016).
6. Kawada, N. et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 44, 1190-1194 (2009).
7. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56, 908-943 (2012).
8. Paradis, V. et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis. Hepatology 49, 851-859 (2009).
9. Leung, C. et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-Alcoholic fatty liver disease. World J Gastroenterol 21, 1189-1196 (2015).
10. Turati, F. et al. Family history of liver cancer and hepatocellular carcinoma. Hepatology 55, 1416-1425 (2012).
11. Dongiovanni, P. & Valenti, L. Genetics of nonalcoholic fatty liver disease. Metabolism 65, 1026-1037 (2016).
12. Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40, 1461-1465 (2008).
13. Valenti, L. et al. Homozygosity for the PNPLA3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51, 1209-1217 (2010).
14. Sookoian, S. & Pirola, C. J. Meta-Analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53, 1883-1894 (2011).
15. Dongiovanni, P. et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 19, 6969-6978 (2013).
16. Donati, B. et al. The rs2294918 E434K Variant Modulates Patatin-Like Phospholipase Domain-Containing 3 Expression and Liver Damage. Hepatology 63, 787-798 (2016).
17. Ruhanen, H. et al. PNPLA3 mediates hepatocyte triacylglycerol remodeling. J Lipid Res 55, 739-746 (2014).
18. Smagris, E. et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 61, 108-118 (2015).
19. Pirazzi, C. et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet 23, 4077-4085 (2014).
20. Mondul, A. et al. PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity. J Nutr 145, 1687-1691 (2015).
21. Liu, Y. L. et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-Alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 61, 75-81 (2013).
22. Valenti, L., Dongiovanni, P., Ginanni Corradini, S., Burza, M. A. & Romeo, S. PNPLA3 I148M variant and hepatocellular carcinoma: A common genetic variant for a rare disease. Dig Liver Dis 45, 619-624 (2013).
23. Trepo, E. et al. Association between the PNPLA3 (rs738409 C > G) variant and hepatocellular carcinoma: Evidence from a meta-Analysis of individual participant data. Hepatology 59, 2170-2177 (2014).
24. Anstee, Q. M., Liu, Y. L., Day, C. P. & Reeves, H. L. Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. J Hepatol 62, 982-983 (2015).
25. Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46, 352-356 (2014).
26. Liu, Y. L. et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-Alcoholic fatty liver disease. Nature communications 5, 4309 (2014).
27. Dongiovanni, P. et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61, 506-514 (2015).
28. Falleti, E., Cussigh, A., Cmet, S., Fabris, C. & Toniutto, P. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis. Dig Liver Dis 48, 69-75 (2016).
29. Buch, S. et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 47, 1443-1448 (2015).
30. Thabet, K. et al. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature communications 7, 12757 (2016).
31. Mancina, R. M. et al. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology 150, 1219-1230 e1216 (2016).
32. Luukkonen, P. K. et al. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-Alcoholic fatty liver disease in humans. J Hepatol (2016).
33. Gijon, M. A., Riekhof, W. R., Zarini, S., Murphy, R. C. & Voelker, D. R. Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils. J Biol Chem 283, 30235-30245 (2008).
34. Pingitore, P. et al. PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Hum Mol Genet (2016).
35. Bjornson, E. et al. Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization. Cell reports 13, 2014-2026 (2015).
36. Li, L. et al. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology 63, 1900-1913 (2016).
37. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-Alcoholic fatty liver disease. J Hepatol 64, 1388-1402 (2016).
38. Piscaglia, F. et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 63, 827-838 (2016).
39. Dongiovanni, P. et al. Statin use and nonalcoholic steatohepatitis in at risk individuals. J Hepatol 63, 705-712 (2015).
40. Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005).
41. Angulo, P. et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846-854 (2007).
42. Valenti, L. et al. Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53, 791-799 (2011).
43. Milano, M. et al. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology 62, 111-117 (2015).
44. Valenti, L. et al. PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma. PLoS One 8, e75982 (2013).
45. Burza, M. A. et al. PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis. Liv Int 34, 514-520 (2014).
46. Purcell, S. et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 559-575 (2007).